Featured Research

from universities, journals, and other organizations

Dual Drug Treatment Prevents Formation Of Colon Tumors In Mice

Date:
August 30, 2000
Source:
Howard Hughes Medical Institute
Summary:
By combining an aspirin-like compound with a drug that inhibits epidermal growth factor activity, scientists have nearly eliminated pre-cancerous colon polyps in mice that are susceptible to developing colon tumors.

August 29, 2000 -- By combining an aspirin-like compound with a drug that inhibits epidermal growth factor activity, scientists have nearly eliminated pre-cancerous colon polyps in mice that are susceptible to developing colon tumors.

If the drug combination strategy makes its way through further animal testing and then through human clinical trials, it could become a powerful preventive therapy for human colon cancer, the second leading cause of cancer deaths in the United States. Currently, more than half of the Western population develops intestinal polyps, and about ten percent of these cases will progress to malignancy.

Howard Hughes Medical Institute (HHMI) investigator Bert Vogelstein, HHMI associate Christopher Torrance and their colleagues at The Johns Hopkins University Oncology Center and Wyeth-Ayerst Research reported that combination therapy of the drugs sulindac and EKB-569 successfully blocked the development of pre-cancerous polyps in mice. The mice possess a genetic defect similar to that found in humans with familial adenomatous polyposis (FAP), a syndrome that confers susceptibility to colon cancer. The researchers published their findings in the September 2000 issue of Nature Medicine.

Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has long been used to help prevent the development of intestinal polyps that can lead to colon cancer. Unfortunately, NSAID use in prevention of colon cancer has been limited because chronic administration of NSAIDs can lead to significant toxicity for patients. EKB-569 is a new drug developed at Wyeth-Ayerst Research that inhibits the activity of the epidermal growth factor (EGF) receptor, which is known to be involved in the development of colon tumors.

The scientists found that the combination of sulindac and EKB-569 achieved a better than 95 percent reduction in the number of cancerous polyps. In contrast, 100 percent of a control group of the mice that did not receive the drugs developed multiple tumors.

"The most surprising thing was that about half the treated mice got absolutely no tumors at all, which was quite unprecedented," said Vogelstein. "And even the animals that did get tumors only had one or two, compared to the untreated control mice which developed an average of 20 tumors. So, we felt very encouraged by these results."

Particularly important, said Vogelstein, is that the use of EKB-569 allowed the scientists to trim the effective dosage of sulindac down to about one-quarter of the amount that produces protection when sulindac alone is administered.

Vogelstein emphasized that the new findings offer general lessons of the importance of research and development on preventive cancer treatments. The power of the dual drug treatment, said Vogelstein, lies in the fact that each drug inhibits a different metabolic signaling pathway important for the generation of malignant cells. While EKB-569 inhibits the EGF signaling pathway, sulindac inhibits cyclooxygenases (COX) and other proteins that stimulate cell proliferation, angiogenesis and other processes key to tumor formation.

"Preventive strategies in general have not been a target of nearly as much research as therapeutic strategies," Vogelstein said. "And the old adage 'an ounce of prevention is worth a pound of cure,' is definitely true for cancers."

Vogelstein said that extensive toxicity testing must be done in animals before clinical trials of the dual-drug therapy can begin in humans. He anticipated that such trials could begin in a year.

"We plan particularly rigorous toxicity trials in animals, because with chemoprevention approaches -- when you're proposing to treat patients who are otherwise healthy -- greater caution is necessary," said Vogelstein. Fortunately, he noted, sulindac has already been used clinically for years, and the combination with EKB-569 allows the dosage of sulindac to be lowered considerably.

In a News & Views article in the same issue of Nature Medicine, Rajnish Gupta and Raymond Dubois at Vanderbilt University Medical Center write: "The results of Torrance et al., may be a harbinger for the eventual development of effective combinatorial regimens for cancer prevention in humans, allowing optimism for the development of effective cancer prevention strategies."


Story Source:

The above story is based on materials provided by Howard Hughes Medical Institute. Note: Materials may be edited for content and length.


Cite This Page:

Howard Hughes Medical Institute. "Dual Drug Treatment Prevents Formation Of Colon Tumors In Mice." ScienceDaily. ScienceDaily, 30 August 2000. <www.sciencedaily.com/releases/2000/08/000830073458.htm>.
Howard Hughes Medical Institute. (2000, August 30). Dual Drug Treatment Prevents Formation Of Colon Tumors In Mice. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2000/08/000830073458.htm
Howard Hughes Medical Institute. "Dual Drug Treatment Prevents Formation Of Colon Tumors In Mice." ScienceDaily. www.sciencedaily.com/releases/2000/08/000830073458.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins